Stryker Corporation (SYK)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$303.13-1.58%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · SYK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 4.9% |
| Our one-year growth estimate | diamond | 11.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 6.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers
SYK — CFO transition
Dated 2026-05-20
Chief Accounting Officer — William E. Berry, Jr.: William E. Berry, Jr. is retiring from his role as Chief Accounting Officer and Emily Baculik will succeed him.
Why it matters: Changes in leadership can affect the company's path and stability. We need clarity.
Watch forThe transition went smoothly with no reported problems.
Also watch forThere are reports of problems after the CFO transition.
Why it matters: New tariffs could raise costs and affect demand. Monitoring this helps assess financial health.
Worry ifHigher product costs are reported. Tariffs are affecting profit margins.
Less concerning ifNo big rise in product costs from tariffs.
Why it matters: A new CFO can change financial strategies and priorities. This could affect investor confidence and future guidance.
Watch forThe new CFO shares a clear and positive financial plan in public.
Also watch forThe new CFO's plan worries investors or analysts.
Why it matters: Keeping this guidance shows faith in earnings growth. It shows management cares about profits.
Supportive ifAdjusted EPS guidance confirmed to be within $14.95 to $15.10.
Worry ifAdjusted EPS guidance is now below $14.95.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$147 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $296 loss on $10,000 · 3.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,758 loss on $10,000 · 27.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The Inari purchase could make Stryker's vascular products better. Progress shows growth.
Supportive ifCompletion of the Inari acquisition by the end of Q1 2025.
Worry ifDelays or failure to finish the Inari purchase.
Why it matters: Keeping EPS guidance is crucial for investor confidence. A cut would raise concerns.
Worry ifManagement says adjusted EPS guidance stays the same.
Less concerning ifManagement lowers adjusted EPS guidance for the year.
Why it matters: This growth rate is the lower end of Stryker's guidance. A miss could signal weakening demand.
Worry ifQ3 organic net sales growth reported below 8.3%.
Less concerning ifQ3 organic net sales growth reported above 9.3%.
Why it matters: This is the lower end of Stryker's adjusted EPS guidance. A miss could indicate earnings pressure.
Worry ifAdjusted EPS in Q3 reported below $14.95.
Less concerning ifAdjusted EPS in Q3 reported above $15.10.
Why it matters: Stryker needs to recover to stay stable and grow. This affects sales and profits.
Supportive ifQ3 shows organic net sales growth above 9.0% and adjusted EPS growth.
Worry ifQ3 shows organic net sales growth below 8.3% and adjusted EPS decline.